RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights, and healthcare intelligence, today announced a strategic ...

The IQV stock gains from its $330-billion addressable market and an enormous trove of data, which is its distinguishing asset.

IQVIA (IQV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Despite a drop in venture funding for digital health companies over the last two-and-a-half years, digital health products and solutions are expanding in...

Stephens initiated coverage of Iqvia with an Overweight rating and $250 price target. The firm says the company has "fulfilled the promise" of combining a leading contract research organization and th...

IQVIA continues to outperform earnings expectations, despite a 14% stock decline, driven by concerns of a CRO industry slowdown and reduced early-stage R&D spending. Q3 results show strong performance...

IQV is known for its innovative use of technology and data analytics.

Evaluate IQVIA's (IQV) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

While the top- and bottom-line numbers for IQVIA (IQV) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare ...

IQVIA Holdings Inc. (NYSE:IQV ) Q3 2024 Results Conference Call October 31, 2024 9:00 AM ET Company Participants Kerri Joseph - Senior Vice President, Investor Relations & Treasury Ari Bousbib - Chair...

Strength in the Research and Development, and Technology and Analytics segments drives IQV's top line in the third quarter of 2024.

Contract research firm IQVIA lowered its annual revenue forecast on Thursday, due to delays in two clinical trials as one of its clients faces logistical challenges.

IQVIA Holdings (IQV) came out with quarterly earnings of $2.84 per share, beating the Zacks Consensus Estimate of $2.81 per share. This compares to earnings of $2.49 per share a year ago.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...

IQV's TAS and RD&S revenues are anticipated to have increased, while CSMS revenues are likely to have dipped in the third quarter of 2024.

Besides Wall Street's top -and-bottom-line estimates for IQVIA (IQV), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quart...

IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its third-quarter 2024 financial results before the market opens on Thursday, October 31, 2024. Th...